A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
A Phase III Randomized Controlled Clinical Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
398 participants
Jul 7, 2026
INTERVENTIONAL
Conditions
Summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after platinum-containing chemotherapy failure.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration by intravenous infusion for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Administration by intravenous infusion for a cycle of 2 weeks.
Oral administration for a cycle of 2 weeks.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07606599